A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of of VSA012 in Subjects with Paroxysmal Nocturnal Hemoglobinuria(PNH)
Not yet recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Visirna Therapeutics HK Limited
- Target Recruit Count
- 16
- Registration Number
- NCT06848296
A Phase I Clinical Study of VSA012 in Healthy Volunteers
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Visirna Therapeutics HK Limited
- Target Recruit Count
- 32
- Registration Number
- NCT06766929
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients
Phase 3
Not yet recruiting
- Conditions
- Homozygous Familial Hypercholesterolemia (HoFH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Visirna Therapeutics HK Limited
- Target Recruit Count
- 45
- Registration Number
- NCT06712771
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Visirna Therapeutics HK Limited
- Target Recruit Count
- 45
- Registration Number
- NCT06322628
A Phase 3 Study of VSA001 in Chinese Adults with Familial Chylomicronemia Syndrome
Phase 3
Active, not recruiting
- Conditions
- Familial Chylomicronemia Syndrome
- Interventions
- Drug: PlaceboDrug: VSA001 injection
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Visirna Therapeutics HK Limited
- Target Recruit Count
- 30
- Registration Number
- NCT05902598
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A VSA003 Phase 1 Study in Chinese Adult Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- DyslipidemiasFamilial HypercholesterolemiaHypertriglyceridemia
- Interventions
- Drug: 0.9% NaCl
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Visirna Therapeutics HK Limited
- Target Recruit Count
- 36
- Registration Number
- NCT05851066
Study of VSA001 Injection in Chinese Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy Adult Volunteers
- Interventions
- Drug: VSA001 injectionDrug: Placebo
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Visirna Therapeutics HK Limited
- Target Recruit Count
- 24
- Registration Number
- NCT05757596
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath